Johnson Fistel has launched an investigation into

SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN) or any of its officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation is focused on investors’ losses and whether they can be recovered under the federal securities laws.

What happens once I have purchased? Elanco Securities? If you have purchased securities and suffered losses on your investment, join our investigation now:

Click here to take part in the survey

For more information contact Jim Baker at [email protected] or (619) 814-4471

There are no costs or obligations to you.

What does Johnson Fistula examine? On June 27, 2024, Elanco issued a press release with updates on the anticipated U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro. According to the press release, Zenrelia is now expected to receive FDA approval in the third quarter of 2024, with a potential launch planned for the fourth quarter of the same year. Elanco had previously established a third quarter launch timeline for Zenrelia. In addition, the press release stated that Credelio Quattro is now expected to receive FDA approval in the fourth quarter of 2024, a departure from the previously forecasted third quarter approval timeline.

Following this news, the company’s stock price fell 20%, closing at $14.28 per share on June 27, 2024.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia and Colorado. The firm represents individual and institutional investors in shareholder class action lawsuits involving derivatives and securities. For more information about the firm and its attorneys, visit http://www.johnsonfistel.com.

Lawyer advertising.
Past results are no guarantee of future results.
Services can be provided by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the distribution of this advertisement and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistula, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]